Severe EBV hepatitis treated with valganciclovir

Area of Science:

• Hepatology
• Virology
• Immunology

Background:

• Primary Epstein-Barr virus (EBV) infection typically causes infectious mononucleosis.
• Severe hepatitis is a rare but serious complication of primary EBV infection, particularly in immunocompetent individuals.
• Corticosteroid therapy is sometimes used for severe EBV hepatitis, but its efficacy can be limited.

Observation:

• An 18-year-old immunocompetent male presented with severe hepatitis secondary to primary EBV infection.
• Initial treatment with corticosteroids led to a worsening of the patient's clinical condition and liver function.
• Oral valganciclovir was added due to its favorable bioavailability and prior positive outcomes in various clinical scenarios.

Findings:

• The addition of oral valganciclovir resulted in a rapid and complete resolution of symptoms.
• Liver function tests normalized, and the patient's overall clinical status improved significantly following valganciclovir administration.
• This case demonstrates the effectiveness of valganciclovir in managing severe EBV-associated hepatitis.

Implications:

• Oral valganciclovir represents a promising therapeutic strategy for severe hepatitis complicating primary EBV infection, even in immunocompetent patients.
• This case challenges the conventional approach and suggests considering antiviral therapy earlier in severe EBV hepatitis unresponsive to corticosteroids.
• Further research into the role of valganciclovir in EBV hepatitis is warranted to establish its definitive place in clinical management.